Illumina (ILMN) vs IQVIA (IQV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Illumina (ILMN) has outperformed IQVIA (IQV) over the past year, gaining 180.9% versus a gain of 28.7%. Over five years, IQV leads with a +3.9% price change compared with -31.9% for ILMN. IQVIA is the larger company by market cap ($42.48 billion vs $40.43 billion), about 1.1 times the size.
On valuation, IQVIA trades at a lower forward P/E (17.9x vs 43.8x for Illumina). Illumina converts more of its revenue into profit, with a net margin of 19.6% versus 8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ILMN | IQV |
|---|---|---|
| Share price | $267.76 | $258.11 |
| Market cap | $40.43B | $42.48B |
| 1-day change | -2.11% | -0.72% |
| YTD return | +107.05% | +14.70% |
| 1-year return | +180.89% | +28.71% |
| 5-year return | -31.90% | +3.89% |
| P/E ratio (TTM) | 49.96 | 32.06 |
| Forward P/E | 43.83 | 17.87 |
| EPS (TTM) | $5.36 | $8.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.34B | $16.31B |
| Revenue growth (YoY) | -0.66% | +5.87% |
| Net income (latest FY) | $850.00M | $1.36B |
| Gross margin | 66.08% | 33.29% |
| Operating margin | 18.58% | 13.38% |
| Net margin | 19.57% | 8.34% |
| 52-week high | $309.35 | $277.40 |
| 52-week low | $88.00 | $154.50 |
| Distance from 52-week high | -13.44% | -6.95% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -16.40% | +12.68% |
| Average volume | 2.66M | 1.44M |
| Shares outstanding | 151.00M | 164.60M |
| Employees | 8,600 | 94,000 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ILMN has outperformed IQV by 152.2 percentage points over the past year.
- Illumina trades at a higher earnings multiple (50.0x vs 32.1x trailing P/E).
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus 8.3 cents for IQVIA.
- IQVIA grew revenue faster in its latest fiscal year (+5.87% vs -0.66%).
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Healthcare · Diagnostics & Research · 8,600 employees
About IQVIA
IQV stock →IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Healthcare · Diagnostics & Research · 94,000 employees
ILMN vs IQV FAQ
Which is bigger, Illumina or IQVIA?
IQVIA (IQV) is larger, with a market capitalization of $42.48B compared with $40.43B for Illumina (ILMN).
Which stock has performed better over the past year, ILMN or IQV?
ILMN returned +180.89% over the past 12 months, compared with +28.71% for IQV (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ILMN or IQV?
IQV has the lower trailing P/E at 32.1, versus 50.0 for ILMN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Illumina and IQVIA in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.